A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response

The Bio Report
|

Automatic TRANSCRIPT

Matt. Thanks for joining us. It's a pleasure nice to meet you. Danny i'm glad to be here. We're going to talk about fos flatten. Its lead therapy. Which has multiple mechanisms of action and how it works to enlist the immune system to kill cancer cells. Let's start with your lead therapeutic. Pt on twelve. Which is a first class. Harrow phosphate platinum conjugate. Break that down in simple terms. What is it thank you. That's a good question. I think maybe i'll just briefly tell you a little bit about the company and how we got to where we are with this molecule. Pt one to foss platin- therapeutics was founded by myself. And our ceo robert fallon my fellow co founder in two thousand ten and we really built the the company around this family of compounds that we in license at the discovery. Stage which comprise these Family of these first in class pi-rre phosphate platinum conjugates and based in new york. Although these days that that means something different than it used to We have a nice Small office here in midtown with our management team. Of course now are all working remotely and we worked our way through preclinical and early clinical development by running collaborations around the world. We've actually had worked ongoing in fifteen countries Since we started and These are academe amick. A- collaborations contract research organizations clinical sites but also industry collaborators We we have a an existing collaboration with pfizer and their co-development partner. Md serono or merck darmstadt on one of the combination programs that were running and we're still private company in early phase two development with pt. One too so to your question about pt to is a small molecule and actually to our knowledge. It's the first anti cancer agent containing a pirate phosphate and This has implications on its safety. Its pharmacokinetics to mechanism of action. And even on its. It's targeting where it's delivery within the body and i'm sure we can get into that further as we go. I generally think of conjugated therapies is linking targeting mechanism to a- warhead. I take it the way. Pt one to works is a bit different. What exactly conjugated in pt. One two and what to each those components do it's a great question i think we. We certainly are not an antibody drug conjugate. I don't want to give that impression. I think we're thinking of conjugation. As a medicinal chemistry term that goes back to certainly before the advent of of adc's in cancer care Our inventor of the late refunder bose was actually the first researcher able to successfully link or conjugate a pyro phosphate to platinum core molecule. And of course Platinum molecules with platinum in their core have been a mainstay of of cancer. Care for some time now. He was really seeking through his work in medicinal chemistry To find a new paradigm for a platinum containing agents he did so by congregating power phosphate. And what that does is because the para phosphate is so strongly linked. It remains intact for the most part in the body theory differently from cytotoxic agents and certainly from other platinum containing agents Pyro phosphate also benign in the body Native to healthy cells so you'll the respiration so we're not adding something that's in and of itself toxic

Coming up next